

Company Heartbeats

Swiss companies - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
23 Apr 26	Schindler	Q1 result	CHF 269.80	Call	SKVBRU	18 Sep 26	11.05	280.00	0.21	Calls on Schindler
24 Apr 26	Kuhne&Nagel	Q1 result	CHF 192.60	Call	S8CBEU	18 Sep 26	8.31	200.00	0.19	Calls on Kuhne&Nagel
24 Apr 26	BB Biotech	Q1 result	CHF 46.00	Call	SH6BCU	18 Sep 26	6.68	48.00	0.31	Calls on BB Biotech
27 Apr 26	Holcim	Q1 result	CHF 71.50	Call	SUZBQU	18 Sep 26	8.78	74.00	0.35	Calls on Holcim
				Put	BSIBMU	18 Sep 26	6.07	70.00	0.53	Puts on Holcim
28 Apr 26	Bucher Ind.	Q1 result	CHF 339.50	Call	S6KBGU	18 Sep 26	8.49	350.00	0.18	Calls on Bucher Ind.
28 Apr 26	Idorsia	Q1 result	CHF 3.74	Call	SG2BTU	18 Sep 26	3.24	4.00	0.12	Calls on Idorsia
28 Apr 26	Novartis	Q1 result	CHF 116.22	Call	SRIBVU	18 Sep 26	10.33	120.00	0.33	Calls on Novartis
				Put	SV3BDU	18 Sep 26	9.54	110.00	0.26	Puts on Novartis
29 Apr 26	Straumann	Semi-annual report	CHF 88.16	Call	S65BLU	18 Sep 26	6.61	92.00	0.30	Calls on Straumann
30 Apr 26	SIG Combibloc	Q1 result	CHF 11.26	Call	SBOBZU	18 Sep 26	6.76	12.00	0.16	Calls on SIG Combibloc
01 May 26	Galderma	Q1 result	CHF 151.00	Call	SGYB7U	18 Sep 26	6.04	160.00	0.21	Calls on Galderma
04 May 26	Sandoz	Q1 result	CHF 63.94	Call	SOYBSU	18 Sep 26	6.98	66.00	0.44	Calls on Sandoz
05 May 26	Logitech	Annual report	CHF 77.72	Call	S19BNU	18 Sep 26	6.33	82.00	0.27	Calls on Logitech
				Put	S43BIU	18 Sep 26	5.18	75.00	0.30	Puts on Logitech

Source: Refinitiv, UBS.

As of: 22 Apr 26. All prices are indicative.

Company Heartbeats

International companies - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
23 Apr 26	SAP	Q1 result	EUR 151.50	Call	BWQSOU	18 Sep 26	6.97	160.00	0.20	Calls on SAP
29 Apr 26	Alphabet	Q1 result	USD 330.47	Call	SJ4BZU	18 Sep 26	7.60	350.00	0.20	Calls on Alphabet
29 Apr 26	Meta Platforms	Q1 result	USD 668.84	Call	SYWBPU	18 Sep 26	6.97	700.00	0.48	Calls on Meta Platforms
29 Apr 26	Microsoft	Q3 result	USD 424.16	Call	BSU4PU	18 Sep 26	7.85	440.00	0.54	Calls on Microsoft
29 Apr 26	Dt.Bank	Annual report	EUR 27.84	Call	BTRSTU	18 Sep 26	8.06	29.00	0.42	Calls on Dt.Bank
29 Apr 26	Amazon.com	Q1 result	USD 249.91	Call	SNQB5U	18 Sep 26	7.28	260.00	0.35	Calls on Amazon.com
30 Apr 26	Apple	Semi-annual report	USD 266.17	Call	SB4B3U	18 Sep 26	9.32	275.00	0.28	Calls on Apple
30 Apr 26	Volkswagen	Q1 result	EUR 89.74	Call	BL7SVU	18 Sep 26	11.28	95.00	0.07	Calls on Volkswagen
30 Apr 26	Eli Lilly	Q1 result	USD 903.02	Call	BZYS3U	18 Sep 26	6.91	950.00	0.64	Calls on Eli Lilly
01 May 26	Moderna	Q1 result	USD 54.23	Call	SYXB3U	18 Sep 26	3.88	60.00	0.74	Calls on Moderna
05 May 26	Paypal	Q1 result	USD 50.88	Call	SNAB2U	18 Sep 26	6.69	55.00	0.07	Calls on Paypal
05 May 26	AMD	Q1 result	USD 284.49	Call	BSPB4U	18 Sep 26	4.59	300.00	0.67	Calls on AMD

Source: Refinitiv, UBS.

As of: 22 Apr 26. All prices are indicative.

Disclaimer

This material has been prepared by UBS AG or one of its affiliates ("UBS"). This material is only intended for the distribution permitted under the applicable law. It has not been prepared for the needs of a specific recipient. It is only published for information purposes and does not constitute an offer or an invitation to purchase or sell securities or associated financial instruments ("Instruments"). UBS accepts no liability (either expressly or tacitly) for the completeness or reliability of the information contained in this document, except for the information on UBS AG and its affiliates. The information should not be regarded by the recipients as a substitute for their own judgment. All the opinions contained herein may change without prior notice and contradict the opinions of other business areas of UBS due to the application of different assumptions and criteria. UBS is not obliged to keep the information up to date. UBS, its executives, employees or clients may have or have had a participation in the Instruments and may conclude transactions with them at any time. UBS may maintain or have maintained a relationship with the entities specified in this information. Neither UBS nor its affiliates, executives or employees are liable for losses resulting from the use of this information.

Structured derivatives do not constitute participation in collective investment schemes. For this reason they do not require approval from the Swiss Financial Market Supervisory Authority (FINMA). As a result, investors are not entitled to the specific investor protection provided by the Swiss Collective Investment Schemes Act (CISA).

Structured products are complex and involve a high risk. The intrinsic value of the investment instruments depends not only on the performance of the underlying asset, but also on the issuer's creditworthiness (credit risk), which can change over the duration of the product. In relation to any securities, currencies, financial instruments or other assets underlying a transaction to which this material relates, the values may fall as well as rise and past performance is not an indication of future performance. Before entering into any transaction, you should consult your own legal, supervisory, tax, financial and accounting advisors as you consider necessary. You should also make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) at your own discretion and based on your consultation with advisors as you consider necessary. Unless expressly agreed otherwise in writing, UBS does not act as financial advisor or fiduciary in any transaction. The terms and conditions of an investment are subject solely to the detailed provisions, including risk considerations, contained in the relevant product documentation. The product documentation, i.e. the prospectus and the Key Information Document (KID), can be obtained from the website keyinvest.ch.en.ubs.com, by entering the relevant security / ISIN. Before you invest in a product, please read the current prospectus and the Key Information Document (KID) carefully and thoroughly. UBS makes no representations or warranties with regard to any information contained herein, which originates from independent sources. This publication may not be copied or reproduced without UBS's prior written permission.

Not for distribution in the United States or to US persons. © UBS 2026. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS. UBS prohibits the forwarding of this information without the approval of UBS.

Contact

keyinvest@ubs.com

+41 44 239 76 76*

ubs.com/keyinvest

*Please note that calls to numbers marked with * may be recorded. When you call these numbers, we assume that you consent to this practice.